ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.105
+0.005 (0.45%)
Aug 5, 2026, 1:02 PM EDT - Market open
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $20.85M in the quarter ending March 31, 2026, a decrease of -9.47%. This brings the company's revenue in the last twelve months to $79.18M, up 4.43% year-over-year. In the year 2025, ADC Therapeutics had annual revenue of $81.36M with 14.85% growth.
Revenue (ttm)
$79.18M
Revenue Growth
+4.43%
P/S Ratio
1.78
Revenue / Employee
$410,233
Employees
193
Market Cap
140.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.36M | 10.52M | 14.85% |
| Dec 31, 2024 | 70.84M | 1.28M | 1.84% |
| Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
| Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
| Dec 31, 2021 | 33.92M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 229.67M |
| Organigram Global | 196.43M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 120.65M |
| SIGA Technologies | 93.78M |
| Journey Medical | 64.68M |
| Cumberland Pharmaceuticals | 44.30M |
| Alpha Teknova | 41.80M |
ADCT News
- 4 weeks ago - ADC Therapeutics Announces New Employee Inducement Grant - PRNewsWire
- 5 weeks ago - ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial - TheFly
- 5 weeks ago - ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial - PRNewsWire
- 6 weeks ago - ADC Therapeutics to reduce workforce by 17% globally - TheFly
- 6 weeks ago - ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities - PRNewsWire
- 2 months ago - ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 months ago - ADC Therapeutics price target lowered to $5 from $8 at Stephens - TheFly
- 2 months ago - ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters